drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody (anti-CTLA-4 checkpoint inhibitor)
drug_description
Fc-enhanced anti-CTLA-4 monoclonal antibody that boosts T-cell priming and can deplete intratumoral regulatory T cells via ADCC.
nci_thesaurus_concept_id
C158557
nci_thesaurus_preferred_term
Botensilimab
nci_thesaurus_definition
An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody botensilimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody.
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fc-engineered anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 to relieve inhibitory signaling and enhance T-cell priming/activation; enhanced Fc effector function enables ADCC-mediated depletion of intratumoral regulatory T cells and increases antibody stability/half-life.
drug_name
Botensilimab
nct_id_drug_ref
NCT06268015